id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2024-D-2033-0004,FDA,FDA-2024-D-2033,Request for Extension from Biotechnology Innovation Organization (BIO),Other,Request for Extension,2024-12-10T05:00:00Z,2024,12,2024-12-10T05:00:00Z,,2024-12-10T16:01:11Z,,0,0,090000648684c0d4
FDA-2024-D-2033-0002,FDA,FDA-2024-D-2033,Expedited Program for Serious Conditions—Accelerated Approval of Drugs and Biologics; Draft Guidance for Industry,Other,Guidance,2024-12-06T05:00:00Z,2024,12,2024-12-06T05:00:00Z,2025-03-07T04:59:59Z,2025-07-16T09:00:27Z,,1,0,090000648684bb37
FDA-2024-D-2033-0001,FDA,FDA-2024-D-2033,Expedited Program for Serious Conditions—Accelerated Approval of Drugs and Biologics; Draft Guidance for Industry; Availability,Notice,Notice of Availability,2024-12-06T05:00:00Z,2024,12,2024-12-06T05:00:00Z,,2025-06-08T00:55:36Z,2024-28392,0,0,090000648684b49a